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Abstract
Background: Previous studies showed that a probiotic-rich diet may improve the plasma lipid profile and lower
the risk of cardiovascular disease (CVD). In a randomized controlled study we tested the possibility for regulation of
plasma lipid profile using a kefir that contained the antioxidative probiotic strain, Lactobacillus fermentum ME-3
(DSM14241). The trial was performed in clinically healthy adults with borderline-high serum low-density lipoprotein-
cholesterol (LDL-C) and/or high serum triglyceride (TG) levels based on guidelines from the European Cardiology
Society and European Atherosclerosis Society.
Methods: One hundred sixty four participants meeting the inclusion criteria were included. Participants were
randomised to receive 200 ml/day kefir, either with probiotic (PG; n = 71, 58 females, mean age 49.6 ± 6.5 y) or
without probiotic (CG; n = 66, 58 females, mean age 49.9 ± 6.1 y). The probiotic contained 4 × 107 cfu/ml L.
fermentum ME-3 (total 8 × 109 cfu/day). At 4 weeks (n = 71 PG and n = 66 CG) and at 8 weeks (n = 43 PG and n = 33
CG), we evaluated anthropologic, blood biochemical indices, and the faecal temporal persistence of the probiotic
strain was assessed by real-time PCR.
Results: After 4 weeks, the lipid profiles were mostly similar between groups: only the values of oxidised LDL
(ox-LDL) and TG were significantly reduced (P < 0.001 and P = 0.005, resp.). After 8 weeks, the PG group exhibited
reductions in LDL-C (5 %, P = 0.001), ox-LDL (6 %, P < 0.0002), TG (17 %, P = 0.033). Next, the ratio of LDL-C to HDL-C
was decreased only in the PG (P = 0.013) while in the CG it was significantly increased (P = 0.018). After completing
the trial the changes in all above listed indices were significantly (P < 0.05) different between the PG and CG
groups. In faeces, the prevalence of L. fermentum ME-3 increased after 4 and 8 weeks (both P < 0.001), but the
counts, determined with real-time PCR, remained constant.
Conclusions: Eight weeks of consuming kefir with the antioxidative probiotic L. fermentum ME-3, reduced serum
LDL-C, ox-LDL and TG values in clinically healthy volunteers with borderline-high lipid profile indices. Thus, L.
fermentum ME-3 has potential to lower the risk of CVD that is tightly associated with maintenance of plasma lipid
profile. This study was registered as current controlled trial http://www.controlled-trials.com/ISRCTN49744186 as
ISRCTN49744186.
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Background
Cardiovascular disease (CVD) is the number one cause
of death worldwide, and its incidence is rapidly increasing
in countries with low- and mid-range economies [1, 2].
Abnormal function of the heart is related to dyslipidae-
mia, identified by the main marker, elevated levels of
low-density lipoprotein-cholesterol (LDL-C), and the
secondary marker, reduced levels of high-density chol-
esterol (HDL-C); these cholesterol disorders are sum-
marized by the ratio of LDL: HDL. Numerous clinical
trials have demonstrated that LDL-C can independently
cause the development and progression of coronary
heart disease [3]. In addition, elevated levels of triglyc-
erides (TG) may contribute to dyslipidaemia. In a re-
cent statement, the European Cardiology Society (ESC)
and European Atherosclerosis Society (EAS) recom-
mended that LDL-C should be used as a primary screen-
ing indicator for CVD risk estimations [4]. Thus, lowering
the level of LDL-C remains the primary target of blood
lipid-regulating strategies, including therapeutic dietary
changes and pharmacological interventions [5].
Gut microbiota is an essential component of the com-
plex host ecosystem involved in nutrition and health. A
wide variety of host, microbiological, dietary, and envir-
onmental factors affect the metabolic relationships be-
tween gut mucosal epithelial cells and microbiota [6–9].
However, it remains unclear what role imbalanced intes-
tinal microbiota might play in the pathophysiology of
atherosclerosis, which underlies CVD. Cholesterol is
obtained both through the diet and through highly-
regulated biosynthesis. Serum cholesterol is predomin-
antly eliminated from body in form of bile acids [10].
Among the normal microbiota of the gastrointestinal
tract, some species and strains of lactic acid bacteria can
assimilate cholesterol from consumed dietary products
[11]. A meta-analysis of 13 probiotic studies indicated
that a probiotic-rich diet improved the plasma lipid pro-
file. Probiotic diets reduced the total cholesterol and
LDL-C concentrations in the plasma of participants with
high, borderline-high, and even normal cholesterol levels
[12]. However, it is not clear how long the intervention
should last to achieve a beneficial effect in healthy vol-
unteers with borderline-high levels of LDL-C.
Lactobacillus fermentum ME-3 (DSM 14241) is a bac-
terial strain of human origin that was isolated from a
healthy one-year-old child. L. fermentum ME-3 had both
antimicrobial and antioxidant properties [13–16]. Vari-
ous clinical studies have demonstrated several health
benefits associated with consuming this strain [17–21].
In the present study, we aimed to evaluate the effects
of the probiotic L. fermentum ME-3 on the plasma lipid
profile in a randomised, double-blind, placebo-controlled,
parallel-design, two-armed study (ISRCTN49744186). We
included clinically healthy Estonian adults that had
borderline-high levels of LDL-C and above optimum
values of serum TG. We evaluated anthropologic, blood,
biochemical, and faecal microbiological indices. Significant
reductions in serum LDL-C and TG were the primary out-
come measures for lowering the CVD risk due to
borderline-high plasma lipid profiles.
Methods
Probiotic lactobacillus strain
The L. fermentum ME-3 strain was previously isolated
from the gastrointestinal tract of healthy Estonian chil-
dren [22]. The strain was deposited in the Deutsche
Sammlung von Mikroorganismen und Zellkulturen
(German Collection of Microorganisms and Cell Cul-
tures GmbH) under the registration number, DSM
14241. The L. fermentum ME-3 strain used in this
study was confirmed by molecular identification with
polymerase chain reaction that employed an internally-
transcribed spacer and 16S rRNA sequencing [23]. The
strain’s safety was confirmed previously in an animal
model [16] and in healthy Estonian adults (registered
trials ISCRNT43435738 and ISCRNT53154826).
Activity for bile hydrolysation
Enzymatic deconjugation of bile acids by the bile salt
hydrolase (BSH) activity of L. fermentum ME-3 was
tested according to Lim et al. [24]. L. fermentum ME-3
strains were cultured overnight on de Man, Rogosa,
Sharpe (MRS; Oxoid, UK) agar in microaerobic condi-
tions at 37 °C. For control cultures, we used three refer-
ence strains (L. acidophilus 821–3, L. plantarum 299v,
and L. plantarum BAA793). After incubation, cultures
were standardised to McFarland 3.0. For testing BSH ac-
tivity, sterilised paper disks were impregnated with the
cultures and placed on MRS agar plates supplemented
with 4 % (w/v) tauro-deoxycholic acid sodium salt
(TDCA, Sigma, USA) and 0.37 g/l CaCl2. The plates
were anaerobically incubated at 37 °C for 72 h, and the
diameters of the precipitation zones around the disks
were measured. BSH activity was then calculated by sub-
tracting the disc diameter (DD, mm) from the inhibition
zone diameter (IZD, mm), and dividing by two, as fol-
lows: BSH activity = (IZD-DD)/2. The activity of three
consecutive cultures of each strain was expressed as me-
dian (CI 95 %) value.
Kefir preparation
The probiotic kefir containing L. fermentum ME-3
(trademark “Hellus”, 2005) was developed at Tere AS in
Estonia. Briefly, kefir was prepared from pasteurised
(92–95 °C for 5 min) cow’s milk with 2.5 % fat content;
L. fermentum ME-3 was added as an adjunct starter.
Commercial starter cultures — including kefir grains
and mesophilic aromatic cultures of Lactococcus lactis
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subsp cremoris, Lactococcus lactis subsp lactis biovar
diacetylactis, Leuconostoc sp, and Lactococcus lactis
subsp lactis (Chr. Hansen, Denmark) — were added to
the incubation tank. For production of “Hellus” kefir,
freeze-dried L. fermentum ME-3 cultures were added to
the kefir milk to a concentration of 1 × 106 colony-
forming units (cfu)/ml. The kefir milk fermentation
process lasted approximately 20–24 h, until achieving
the required pH 4.5. After fermentation, the kefir was
cooled to 8-10 °C in a heat exchanger.
The final kefir product possessed a homogenous
consistency, creamy colour, shiny smooth surface, fresh
and acidic taste, and mild yeast-like aroma. The average
nutritional value of 100 g kefir was as follows: energy
content 217 kJ/52 kcal, 3.1 g protein, 4.2 g carbohy-
drate, and 2.5 g fat. The content of L. fermentum
ME-3 in the probiotic kefir was 4 × 107 cfu/ml. Simi-
lar kefir produced without the probiotic adjunct served as
a control.
Subjects
This randomised, double-blind, placebo-controlled, parallel-
design, two-armed study (registered trial ISRCTN49744186)
was conducted in South Estonia, according to the guide-
lines laid down in the Declaration of Helsinki 1996–2000.
The study was approved by the Ethics Committee of the
University of Tartu (protocol number 210/T-3; 18.01.2011).
All participants signed the written informed consent at
enrolment and were given the option to withdraw from
the study at any time.
Subject inclusion criteria were a desire to partici-
pate; age 35–65 years; blood lipid fractions: total chol-
esterol >5.2 mmol/l, LDL-C >3.4 mmol/l, and/or TG
>1.7 mmol/l, in addition, subjects had to be willing to
maintain a stable diet and physical activity level. Ex-
clusion criteria included a history of gastrointestinal
disease; food allergy or acute infection; use of any anti-
microbial agent within the preceding 2 months; use of any
regular concomitant medication within the preceding
2 weeks, including non-steroidal anti-inflammatory drugs
and antioxidant products; pregnancy or breastfeeding; any
serious organ or systemic disease; high blood pressure
(>140/95 mmHg); eating disorder; extensive exercise; gen-
etic hyperlipidaemia; drug or alcohol abuse; active weight
loss >5 kg in the prior 3 months; participation in other
studies within the last 30 days or during the study; and
not wishing to participate. Also, subjects were excluded
when they had used any concomitant treatment within
the preceding 2 months that could influence evaluation of
the efficacy and tolerability of the investigational study
product, including lipid-lowering drugs (e.g., statins, bile
acid sequestering agents, cholesterol absorption inhibitors,
nicotinic acid) or dietary supplements (e.g., omega-3 fatty
acids, calcium, oat fibre, niacin, green tea extract, plant
sterols, soy protein, psyllium seed husk, or probiotics/
prebiotics).
Participants were randomly assigned to receive either
probiotic or placebo using a computer-generated ran-
domisation list prepared by the independent statistician.
The 164 eligible subjects were randomised to receive ei-
ther probiotic treatment (PG; n = 83) or control kefir
(CG; n = 81; Fig. 1).
The sample size was calculated for a two-armed inter-
vention investigation that included 4 weeks of probiotic
kefir consumption. We assumed a predicted change of
0.2 U in the LDL-C level between the probiotic and con-
trol groups during the treatment period. The planned
sample size of 83 subjects provided sufficient power
(0.90) to detect a significance level of P < 0.05 with the
Student’s t-test.
Study protocol
Each group consumed 200 ml/day of kefir without (CG)
or with (PG) the probiotic L. fermentum ME-3. The total
amount of L. fermentum ME-3 consumed was 8 ×
109 cfu/day. The trial lasted for 8 weeks. The weekly
food diary was not performed but the appearance of
gastrointestinal complaints was registered (Fig. 1). Mea-
surements were carried out at the start of the study
(baseline values) with 164 participants that met the in-
clusion criteria. We conducted measurements at 4 weeks
with 137 participants (n = 71 PG and n = 66 CG) while
27 subjects withdrew (n = 12 PG and n = 15 CG) due to
respiratory infections, intestinal complaints, and loss of
contact. At 8 weeks 76 participants (n = 43 PG and n =
33 CG) were followed; while 51 subjects withdrew due
to the infections, loss of contact and motivation (Fig. 1).
Clinical investigations
Subjects in both groups habitually consumed a Western-
type diet, typically rich in potatoes, vegetables, meat,
eggs, but also characterised with a high content of fibre
(black bread) and several dairy products. The trial code
was broken after 8 weeks. At each measurement time-
point (baseline, 4 and 8 weeks), the subjects underwent
a clinical examination. Plasma samples were collected
after an overnight fast and abstinence from any medica-
tions, tobacco, alcohol, tea, and coffee. Each participant
was evaluated for anthropometric indices. Body mass
index (BMI) was calculated as the weight (kg) divided by
squared height (m2) [25]. A sphygmomanometer was
used to measure blood pressure, after subjects rested for
5 min in the sitting position. After the blood pressure
measurement, blood samples were collected. Markers
for determining cardiovascular health were selected
based on suggestions by the NDA of the European Food
Safety Authority [26]. At baseline, the two groups did
not significantly differ in the selected anthropometric,
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clinical, and biochemical indices (Table 1). Similarly, at
the end of the trial (8 weeks), the PG comprised 36
women and 7 men, with mean BMI 26.5 kg/m2, and
mean age 50.4 y; the CG comprised 30 women and 3
men, with mean BMI 27.1 kg/m2, mean age 50.8 y. The
two groups showed no significant differences. All vol-
unteers were considered clinically healthy according to
the tested baseline and reference values (Nordic Refer-
ence Interval Project; NORIP). Significant reductions in
serum LDL-C and TG were considered the primary
outcome measures for lowering the CVD risk score.
The obtained faecal samples were stored in a domestic
refrigerator at 4 °C for no more than 2 h before trans-
portation to the laboratory. There, the samples were fro-
zen at −80 °C until analyses for determining the L.
fermentum ME-3 prevalence and counts.
Measurement of oxidized LDL
Oxidized LDL (oxLDL) was measured with an ELISA kit
(Cat. No. 10-1143-01, Mercodia AB, Uppsala, Sweden)
[17]. This solid-phase, two-site enzyme immunoassay
was based on the direct sandwich technique, in which
two monoclonal antibodies were directed against separ-
ate antigenic determinants on the oxidized apolipopro-
tein B molecule [27]. During incubation, oxLDL in the
sample reacted with the anti-oxLDL antibodies bound to
the microtitration wells. After washing, a peroxidase-
conjugated anti-human apolipoprotein B antibody re-
cognised the oxLDL bound to the solid phase. After a
second incubation and washing, the bound conjugate was
detected in a reaction with 3,3′,5,5′-tetramethylbenzidine.
The reaction was stopped by adding acid, and the colour
intensity (U/l) was measured spectrophotometrically at
450 nm.
Metabolic indices (plasma glucose, total cholesterol,
LDL-C, HDL-C, and TG) were analysed with standard
laboratory methods and certified assays in the clinical la-
boratory of the Tartu University Clinics, Estonia. As ref-
erences, we used indices for routine laboratory tests
proposed by the Nordic Reference Interval Project
(NORIP, http://www.tandfonline.com/doi/pdf/10.1080/
00365510410006324#.Vhpmx27-VCE).
Molecular assessment of L. fermentum ME-3
Bacterial DNA was extracted from faecal samples with a
QIAamp DNA stool mini kit (QIAgen, Hilden, Germany)
with some modifications. Faeces (0.22 g) was suspended in
200 μl TE buffer (10 mM Tris, 10 mM EDTA pH 8,
20 mg/ml lysozyme, and 200 U/ml mutanolysin), and in-
cubated for 1 h at 37 °C. To these samples, we added 0.3 g
of 0.1-mm zirconia/silica beads and 1.4 ml ASL solution
from the stool mini kit. The tubes were then agitated for
3 min at 5000 rpm in a mini-bead beater (Biospec
Products Inc., USA). The protocol was completed as
described by the manufacturer (QIAgen, Germany).
To establish a quantitative assay, we created plasmids
that contained the PCR-amplified region of target bacteria
with the pGEM-T vector system (Promega, Madison, WI).
The PCR amplicon derived from L. fermentum ME-3 was
inserted into the plasmid vector, and the recombinant
Fig. 1 Flow chart of the study subjects. Legend: Randomised, double-blind, placebo-controlled, parallel-design, two-armed study (registered trial
ISRCTN49744186). Participants were randomly assigned to receive either probiotic or placebo using a computer-generated randomisation list prepared
by the independent statistician. The 164 eligible subjects were randomised to receive either probiotic treatment (PG; n = 83) or control kefir
(CG; n = 81). The measurements were performed at 4 weeks with 137 participants (n = 71 PG and n = 66 CG) while 27 subjects withdrew. At
8 weeks 76 participants (n = 43 PG and n = 33 CG) were followed; while 51 subjects withdrew
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vector was transformed into chemically competent E. coli.
Plasmids were purified with a MaxiPrep kit (Qiagen), and
then, serially diluted, and finally, measured in a spectro-
photometric analysis (Quibit™, Invitrogen) [28]. The target
DNA was quantified by comparing with serial, 10-fold di-
lutions (101 to 105 plasmid copies) of previously quantified
plasmid standards. Comparisons between the plasmid
standards and samples were run in triplicate.
Real-time PCR was performed with the ABI PRISM
7500 HT Sequence Detection System (Applied Biosys-
tems, USA) equipped with optical grade 96-well plates.
For detection of L. fermentum ME-3, the reaction mix-
ture (25 μl) for the TaqMan assay contained 2× TaqMan
Universal PCR Master Mix (PE Applied Biosystems,
USA), 25 pmol primers (ME31 forward: 3′-CTTTTTAC
CGCCAAAAGCAG-5′; ME-3 reverse: 3′-AGCCCTT
GTCGGTGATATTG-5′), 10 pmol of TaqMan probe
(5′-FAM-TTGACACAGACTCGAGCAGT-Tamra-3′),
and 200 ng of extracted DNA. The thermocycling
program included an initial cycle of 95 °C for 10 min,
followed by 45 cycles of 95 °C for 10 s and 60 °C for
1 min. Data was analysed with Sequence Detection Soft-
ware, version 1.6.3 (Applied Biosystem, USA). L. fermen-
tum ME-3 quantities were expressed as the log10 number
of gene copies/g faeces.
Statistical analysis
Statistical analyses were performed with the R pro-
gram, v. 3 · 0 · 2 (A Language and Environment, http://
www.r-project.org) and GraphPad Prism, version 4 · 00
for Windows (GraphPad Software, San Diego, CA). All
data were expressed as the mean and standard devi-
ation (SD; Tables 1 and 2) or as the medians with two-
sided confidence intervals for counts of BHS and L.
fermentum ME-3. Sex and temporal colonisation with
probiotic bacteria were compared between groups with
Fisher’s exact test (Table 1, Fig. 3). Baseline and interven-
tion data (BL 1–4 and BL 2–8 weeks) were compared with






(n = 71) (n = 66) P-values
Sex (female/male) 58/13 58/8 0.443
Age (y) Mean (SD) 49.6 (6.5) 49.9 (6.1) 0.821
Median (percentile 25–75 %) 50 (45–54) 49 (46–54)
Body mass index (kg/m2) Mean (SD) 25.9 (3.8) 26.7 (4.1) 0.277
Median (percentile 25–75 %) 26.6 (23–29) 26.2 (24–29)
Systolic blood pressure (mmHg) Mean (SD) 117.2 (13.8) 119.6 (11.2) 0.271
Median (percentile 25–75 %) 116 (106–129) 119 (113–126)
Diastolic blood pressure (mmHg) Mean (SD) 77.7 (8.9) 81.1 (8.4) 0.022
Median (percentile 25–75 %) 77.5 (72–83) 81.8 (75–85)
Fasting glucose (mmol/l) Mean (SD) 4.8 (0.5) 4.6 (0.6) 0.218
Median (percentile 25–75 %) 4.8 (4.4–5.1) 4.6 (4.4–4.9)
HbA1c (%) Mean (SD) 5.8 (0.3) 5.7 (0.3) 0.467
Median (percentile 25–75 %) 5.8 (5.6–6.0) 5.7 (5.5–6.0)
Total cholesterol (mmol/l) Mean (SD) 5.9 (0 · 7) 6.0 (0.8) 0.584
Median (percentile 25–75 %) 5.8 (5.4–6.2) 5.9 (5.3–6.5)
LDL cholesterol (mmol/l) Mean (SD) 3.8 (0.7) 3.7 (0.8) 0.441
Median (percentile 25–75 %) 3.8 (3.3–4.3) 3.7 (3.2–4.1)
HDL cholesterol (mmol/l) Mean (SD) 1.7 (0.5) 1.8 (0.5) 0.109
Median (percentile 25–75 %) 1.5 (1.3–2.1) 1.8 (1.5–2.1)
LDL-C:HDL-C ratio Mean (SD) 2.4 (0.9) 2.2 (0.8) 0.110
Median (percentile 25–75 %) 2.3 (1.8–3.1) 2.1 (1.7–2.6)
Triglyceride (mmol/l) Mean (SD) 1.2 (0.7) 1.1 (0.5) 0.706
Median (percentile 25–75 %) 1.0 (0.7–1.5) 0.9 (0.8–1.2)
Data represent the mean ± standard deviation and median (CI 25 % and 75 %). For continuous variables, the differences between groups were tested with the
Student’s t-test, and gender distributions were compared with Fisher’s exact test. The only statistical difference was found in the level of diastolic blood pressure
(NORIP, http://www.tandfonline.com/doi/pdf/10.1080/00365510410006324#.Vhpmx27-VCE)
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Table 2 The impact of consumption of probiotic or control kefir for 4 and 8 weeks on biochemical indices of blood sera in healthy subjects
Indices Probiotic group (PG) Control group (CG) Extent of changes between
PG and CGMean (SD) Mean (SD) Mean (SD) Mean (SD)
p= p= p= p= p=
Baseline 1 4 weeks Baseline 1
vs 4 weeks
Baseline 2 8 weeks Baseline 2
vs 8 weeks
Baseline 1 4 weeks Baseline 1
vs 4 weeks






n 71 n 71 n 43 n 43 n 66 n 66 n 33 n 33
Total cholesterol
(mmol/L)
5.9 (0.7) 6.0 (0.8) 0.259 5.9 (0.9) 5.7 (0.8) 0.257 6.0 (0.8) 6.1 (0.9) 0.364 6.2 (1.0) 6.2 (0.9) 0.031 0.798 0.019
HDL cholesterol
(mmol/L)
1.7 (0.5) 1.7 (0.5) 0.943 1.7 (0.4) 1.6 (0.4) 0.229 1.8 (0.5) 1.8 (0.5) 0.001 1.8 (0.5) 1.8 (0.5) 0.385 0.025 0.551
LDL cholesterol
(mmol/L)
3.8 (0.7) 3.8 (0.7) 0.083 3.8 (0.7) 3.6 (0.7) 0.001 3.7 (0.8) 3.8 (0.8) 0.822 4.0 (0.8) 4.0 (0.7) 0.736 0.298 0.037
LDL-C/HDL-C 2.5 (0.9) 2.4 (0.9) 0.303 2.5 (0.8) 2.4 (0.8) 0.013 2.2 (0.8) 2.3 (0.8) 0.001 2.3 (0.7) 2.4 (0.7) 0.018 0.014 0.004
Oxidized LDL (U/L) 53.7 (15.1) 50.8 (14.0) ˂0.001 52.7 (14.1) 50.4 (14.4) ˂0.001 50.5 (12.5) 49.6 (12.3) 0.164 51.0 (11.2) 50.8 (11.6) 0.630 0.103 0.0002
Triglycerides
(mmol/L)
1.2 (0.7) 1.0 (0.5) 0.005 1.0 (0.4) 1.0 (0.6) 0.033 1.1 (0.5) 1.0 (0.4) 0.165 1.0 (0.4) 1.1 (0.3) 0.507 0.244 0.044
Glucose (mmol/L) 4.8 (0.5) 4.8 (0.5) 0.294 4.8 (0.4) 4.9 (0.6) 0.649 4.6 (0.6) 4.7 (0.6) 0.279 4.7 (0.6) 4.7 (0.6) 0.472 0.834 0.964
HbA1c (%) 5.8 (0.3) 5.5 (0.4) ≤0.001 5.4 (0.2) 5.5 (0.2) ≤0.001 5.7 (0.3) 5.6 (0.3) ≤0.001 5.4 (0.2) 5.4 (0.2) ≤0.001 0.220 0.719
Data represent the mean (standard deviation. BL 1 data were comprised of n = 71 volunteers of PG group and n = 66 volunteers of CG who completed the trial at 4 week; BL 2 data comprised of n = 43 volunteers
(PG ) and n = 33 (CG) completing the trial at 8 weeks. Baseline 1 and 2 and intervention data (4 weeks and 8 weeks, resp) were compared with a paired t-test within groups, and extent of changes between PG and CG













a paired t-test or with a Wilcoxon signed-rank test, ac-
cording to the data distribution (Table 2). The change
(mean ± SD) of individual biochemical indices from base-
line of particular participants to 4 and 8 weeks in the pro-
biotic and control groups was assessed with the paired
t-test (Fig. 2). The extent of changes between probiotic
and control groups (the PG and CG groups) was com-
pared with the t-test. Differences were considered statisti-
cally significant when P was <0.05 (Table 2).
Results
Bile salt hydrolysis activity
The bile salt hydrolysis activity (BSH) of L. fermentum
ME-3 and L. plantarum BAA793 was equal: in both the
median (CI 95 %) was 1.5 (1.5). Still it was somewhat
higher than those of the other two control strains, L.
acidophilus 821–3 and L. plantarum 299v with 1.0 (1.0)
and 0.5 (048–1.48), respectively.
Changes in body mass index, blood pressure and lipid
fractions
Consumption of probiotic kefir for 4 or 8 weeks did not
influence the BMI nor blood pressure values. No BMI or
blood pressure changes were observed in either the PG
or CG (data not shown).
After 4 weeks, the lipid profiles were mostly similar
between groups. Still, the TG level in the PG was re-
duced (P = 0.005), and this effect was sustained at
8 weeks of probiotic kefir consumption (17 % reduction,
P = 0.033). The ox-LDL levels also decreased with pro-
biotic intervention. In the PG, the ox-LDL decreased by
5 % at 4 weeks (P < 0.001) and by 6 % (P < 0.001) at
8 weeks, but no change was observed in the CG.
After 8 weeks of intervention, the PG group exhib-
ited significant reduction in LDL-C (5 %, P = 0.001).
Thus, after this period the differences between the
PG and CG groups in the LDL-C, ox-LDL and TG
indices (P = 0.037; 0.0002; 0.044; Fig. 2) could be well
demonstrated.
Additionally we found that, in the CG, the total
cholesterol level was increased from 6.0 mmol/l at
baseline to 6.2 mmol/l after 8 weeks of kefir con-
sumption (P = 0.031), which trend was not detected in
the PG. To characterise additional clinically important
changes in the lipid profile (also known as the
atherogenic index), we calculated the ratio of LDL-C
to HDL-C (Table 2). After 8 weeks, this ratio was de-
creased only in the PG (P = 0.013) while in the CG it
was significantly increased (P = 0.018). As a result, the
extent of changes between groups in total cholesterol
and LDL-C/HDL-C ratio occurred significant (P values
0.014 and 0.004, respectively) which showed a beneficial
effect from the probiotic kefir intervention absent with or-
dinary kefir.
Glycated haemoglobin (HbA1c)
Glycated haemoglobin levels were reduced after 4 and
8 weeks in both the PG and CG. However, no significant
Fig. 2 The reported changes, from the adjusted baseline 2 to 8 weeks,
for individuals in the probiotic and control groups. Legend: Changes
(mean ± SD) are shown for (LDL serum LDL-C, (TG) serum TG, and
(oxLDL) serum oxLDL (paired t-test); the extent of changes was
compared between probiotic and control groups (unpaired t-test)
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shifts were observed in the corresponding glucose values
(Table 2).
Molecular detection of L. fermentum ME-3 with
real-time PCR
The prevalence and counts of probiotic bacteria were
evaluated in the collected faecal samples with real-time
PCR and specific L. fermentum ME-3 primers. At base-
line, L. fermentum ME-3 was found in samples from 10
individuals. The PG exhibited significant increases in the
prevalence of L. fermentum ME-3. Only 8 % of subjects
harboured L. fermentum ME-3 at baseline, but the
prevalence rose to 62 % at 4 weeks and 56 % at 8 weeks
(both P < 0.001) (Fig. 3). These results suggested that
more than half the volunteers in the PG exhibited tem-
poral colonization by L. fermentum ME-3.
The median counts did not change over time; at base-
line, the median (CI 95 %) was 3.31 (2.20–4.95) log10
gene copies/g faeces, and at 4 and 8 weeks, the median
counts were 4.83 (4.47–4.40) and 4.40 (4.11–4.67) log10
gene copies/g faeces, respectively.
Discussion
The present randomised, double-blind, placebo-controlled,
parallel-design, two-armed study (ISRCTN 49744186)
aimed to evaluate whether consumption of a functional
dairy food product could cause reductions in borderline-
high serum LDL-C and serum TG values in Estonian
adults. The main finding of our study was the positive
primary outcome: the significant reductions in LDL-C
(5 %) and TG (17 %) levels in the volunteers that con-
sumed probiotic kefir with L. fermentum ME-3 for
8 weeks. Present results show that daily consumption
of kefir with antioxidative BSH-active L. fermentum
ME-3 (DSM14241) over longer period of time is effica-
cious for regulating the lipid profile in borderline
hyper-cholesterolaemic subjects. This finding supports
the numerous clinical trials [3, 4] having demonstrated
that LDL-C reduction is the main factor in prevention
of the development of coronary heart disease. Earlier
studies have demonstrated that some lactic acid bac-
teria, such as L. plantarum 299v and L. acidophilus L1,
could lower LDL-C levels [29, 30], and that L. reuteri
NCIMB 30242 after different periods of consumption
(from 4 to 6 weeks) reduced both LDL-C and total
cholesterol levels of adults [31]. In children with dyslip-
idemia a formulation of three strains of bifidobacteria
caused up to 4 % reduction of TG and LDL-C values
after 3 months consumption [32]. In contrast, other
probiotic preparations, such as VSL#3 comprising dif-
ferent probiotic strains of Lactobacillus and Bifidobac-
terium species reduced the TG levels in critically ill
patients, but did not influence the LDL-C [33]. In the
present investigation, the gut microbial ecosystem was
the target of the probiotic Lactobacillus sp., and the ke-
fir served as a probiotic carrier. The antioxidative and
anti-atherogenic effects of L. fermentum ME-3 were
previously described in numerous in vitro experiments,
animal experiments, and in human trials, with different
dairy products, including goat milk, cheese, and yog-
hurt [14, 16–19].
The positive effects of lactobacilli on various markers
of lipid metabolism in the human body are likely due to
the sum of multiple different mechanisms [34]. Pereira
et al. [35] demonstrated that short-chain fatty acid con-
centrations, specifically the molar proportion of propi-
onate and/or bile salt deconjugation, comprised the
major mechanism involved in the purported cholesterol-
lowering properties of L. fermentum. Lee et al. (2010) re-
vealed that several regulatory proteins mediated serum
cholesterol reduction by a probiotic strain [36]. Lactic
acid bacteria, including L. fermentum strains, could as-
similate cholesterol, and thus, lower serum cholesterol
levels [37]. However, the effect of Lactobacillus spp.
strains on levels of serum cholesterol and cholesterol frac-
tions is strain-specific, and depends on the origin, proper-
ties and formulation of a certain strain [38–40]. In the
present study, the human origin strain, L. fermentum ME-
3, exhibited considerable BHS activity. Moreover, we
found that the reduction in LDL-C level was consistent
with previous data that showed that L. fermentum ME-3
reduced the serum ox-LDL levels [17–19].
Another potential mechanism involved in the cholesterol-
lowering properties of L. fermentum is related to the
observation that L. fermentum ME-3 showed strong
glycosyl-hydrolase activities. These activities included
alpha-galactosidase, beta-galactosidase, alpha-glycosidase,
beta-glycosidase, and beta-glycuronidase [41]. The
concerted actions of these enzymes derived from L.
fermentum caused the release of a number of bioactive
Fig. 3 Prevalence (%) of L. fermentum ME-3 observed among faecal
samples obtained from subjects in the probiotic and control groups.
Legend: The presence of L. fermentum ME-3 was determined with
real-time PCR and L. fermentum ME-3-specific primers. The baseline
values represent the numbers of BL1 both for PG and CG
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compounds from various large complexes formed from
foodstuffs; some of these bioactive compounds could
affect the blood lipid profile [37]. For example, some
aglycones derived from food-borne glycosides had posi-
tive effects on the blood lipid profile by increasing hep-
atic fatty acid oxidation and inhibiting cholesterol
synthesis [42–44].
Additionally, it is widely known that the high post-
prandial response of serum TG is related to an elevated
insulin response and an elevated hepatic synthesis of
TG and cholesterol. We recently showed that con-
sumption of L. fermentum ME-3 kefir after a standard
breakfast led to a significantly reduced postprandial TG
response [18]. This result may also contribute to the
positive effects of L. fermentum ME-3 on the blood
lipid profile, when it is consumed long-term, like that
established in the present study. It was remarkable that
L. fermentum ME-3 consumption reduced the TG more
rapidly (4 weeks vs. 8 weeks) than it impacted the LDL-
C levels.
In the present study, we tested healthy volunteers with
borderline-high levels of lipid fractions at baseline. This
design enabled us to document the efficacy of L. fer-
mentum ME-3 consumption. Other authors have also
highlighted a need to select groups with borderline
values of biomarkers from the general population [12].
The present study recruitment design was quite similar
to that used in testing efficacy in individuals with dis-
eases, where the proved diagnosis served as the basis
for consecutive patient selection. In our study, all ran-
domly selected individuals of both intervention groups
were healthy and agreed to maintain a standard Western-
type diet rich in potatoes, vegetables, meat, eggs, one also
characterized by a high content of grain fibre and dairy
products. A limitation of this study is that there is no
evaluation of the dietary intake in terms of its possible im-
plications. Variations in diet over weeks may be respon-
sible for some of the changes observed in lipid profile
between probiotic and ordinary kefir. However, none of
the routine clinical indices such as body mass index or
blood pressure changed either in the probiotic or control
groups. Thus the work presented here suggests the special
regulation of the host lipid metabolism with a probiotic
strain Lactobacillus fermentum ME-3. The main limitation
of this study was the high number of drop-outs. Remark-
ably, only two persons in the PG and two in the CG com-
plained of gastrointestinal symptoms, the other drop-out
persons were affected mainly with an outbreak of respira-
tory infections or discontinued the intervention for loss of
motivation to follow the prescriptions during the long
study. However, we observed significant changes in the
primary outcome measure LDL-C.
Previous studies have shown particularly good faecal
recovery of L. fermentum ME-3 after consumption of
probiotic yoghurt and cheese [17, 45]. The probiotic ke-
fir tolerates the technology involved in preparation, and
it remains viable throughout its shelf life [18]. However,
the probiotic strain was detected in only 62 % of faecal
samples after 4 weeks and 56 % after 8 weeks. These re-
sults may be due to the relatively low dose consumed
(8 × 109 cfu/day). Saxelin et al. (1995) reported that a
dose above 1010 cfu/day was necessary for even brief
persistence of a probiotic strain [46]. Nevertheless, the
L. fermentum ME-3 counts in positive faecal samples
were quite high (up to 106 copy numbers/g) and the
beneficial shifts in lipid profiles confirmed the presence
of L. fermentum ME-3 in the gut, seemingly in the
higher parts, where metabolites are absorbed. A recent
clinical trial tested 3 weeks of consuming probiotic
cheese with 2 × 1010 cfu/day of L. plantarum Tensia.
Similarly, faecal recovery was detected in only 64 % of
patients on a hypocaloric diet, although compliance was
high, due to strict control by a hospital nurse [47].
Moreover, the faecal counts of L. plantarum Tensia did
not exceed 103gene copies/g, which was substantially
lower than with L. fermentum ME-3. Our results sug-
gested that the intervention should last at least 8 weeks,
based on the expected primary outcome, despite the
equivalent prevalence of L. fermentum ME-3 temporal
colonization after 4 and 8 weeks. Interestingly, the
prevalence of L. fermentum as species was reported to
be 21 % in Estonian adults [48]. In the present study, we
found that 9 % of subjects at baseline were persistently
colonized with L. fermentum ME-3 strain.
In Estonia, L. fermentum ME-3 has been marketed for
the past 10 years in dairy products. This may have facili-
tated its symbiosis with the hosts. In future investiga-
tions, it would be interesting to assess how a sustainable
colonization of the probiotic strain is influenced by base-
line data of different indigenous lactobacilli to regulate
the health indices of the general population.
It was recently shown that total cholesterol does not
rank very high in either its long-term impact or as a
lipid marker, in terms of its clinical validity, response to
changes in therapy, and long-term signal-to-noise ratio
[2] Thus, our findings that the probiotic L. fermentum
ME-3 had a beneficial effect on LDL-C, ox-LDL, the
LDL-C to HDL-C ratio, and TG levels indicated that the
blood lipid anti-atherogenic profile had improved, which
translated as a reduced risk of CVD.
Conclusion
Eight weeks of consuming kefir with the antioxidative
probiotic L. fermentum ME-3, reduced serum LDL-C,
ox-LDL and TG values in clinically healthy volunteers
with borderline-high lipid profile indices. Thus, L. fer-
mentum ME-3 has the potential to lower the risk of
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CVD that is tightly associated with maintenance of
plasma lipid profile.
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